This post is presented by our media partner Psychedelic News Wire
View the original article here.
Over the last couple of years, interest in psychedelics and their therapeutic potential has risen significantly. Psychedelics such as psilocybin have shown to be useful in treating a variety of conditions, including anxiety, addiction and depression.
Psilocybin is the primary psychoactive compound found in some species of hallucinogenic mushrooms. When administered, this compound synthesizes into psilocin and interacts with an individual’s serotonin receptors, altering their state of consciousness and giving way to changes in their mood as well as their perception of things.
Researchers have uncovered a lot about how psilocybin affects an individual’s behavior and brain. Below, we look at some studies that explore the compound’s potential, offering insight into its mechanisms of action and looking at its application in different conditions.
Psilocybin on anorexia nervosa
This study, which was recently published in “Molecular Psychiatry,” suggests that psilocybin may help individuals maintain their body weight better while also improving their cognitive flexibility. It should be noted that researchers used rat models for their study, and more research is needed to confirm these findings in people.
Psychedelic-assisted therapy for alcohol use disorder
A separate study looked at the impact of psilocybin-assisted therapy on the brain function of individuals with alcohol use disorder. The study, whose findings were reported in “Scientific Reports,” suggests that psilocybin can improve emotional processing and reduce the need for alcohol.
Despite these positive findings, further study is needed to test out these findings on a larger and more diverse population.
Psilocybin on exploration and learning
Research has also looked into how psilocybin affects reinforcement learning, with researchers observing that the psychedelic helped maintain learning capabilities and enhanced rates of learning when higher doses were administered. The researchers noted that further study was required to fully understand the drug’s impact.
Long-Covid and psilocybin
One case study examined the use of psilocybin and MDMA to help manage symptoms of long-Covid. The patient observed huge improvements in cognitive function, depression, anxiety and overall well-being after their psilocybin sessions.
In their report, the researchers highlight the need for more controlled studies testing psychedelics’ effectiveness in long-Covid management.
New cluster headache treatment
Research that looked into psilocybin’s potential in decreasing cluster headache frequency determined that the psychedelic saw an almost 50% drop in headache attacks. The researchers reported their findings in the “Journal of the Neurological Sciences.”
Psilocybin on brain connectivity
Investigators have determined that psilocybin gives rise to a state of hyperconnectivity in the brain. Their findings were reported in “Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.”
Plenty of effort is also being directed by companies such as Seelos Therapeutics Inc. (NASDAQ: SEEL) toward leveraging the medicinal potential of psilocybin. It may not be long before approved psychedelic medicines hit the market.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
This post was originally published by our media partner here.
